🟧 Definium Therapeutics at Leerink Partners Global Healthcare Conference 2026 🟧

Definium Therapeutics discusses their ongoing clinical trials involving LSD and MDMA at the Leerink Partners Global Healthcare Conference 2026. The pharmaceutical company outlines their recent developments and trial progress for treating generalized anxiety and depressive disorders, highlighting promising results from several key studies. The leadership emphasizes their focus on scaling and commercialization efforts while maintaining clinical rigor. Their strategy centers on achieving consistent therapeutic outcomes and navigating the intricacies of long-term patient monitoring. Future plans involve data readouts and expanding pipeline programs to address significant unmet medical needs in psychiatry.